The Trump administration has decided not to go forward with a proposal for Medicare and Medicaid to cover high-demand obesity ...

Pa., said Mounjaro changed his life with 'significant' health benefits. He's calling for widespread access to GLP-1 ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

CMS has historically prohibited coverage of these drugs under Medicare Part D, a relic of a decades-old federal statute that excluded "agents when used for anorexia, weight loss, or weight gain ...

The Centers for Medicare and Medicaid Services recently ... a proposal initiated by the Biden Administration to cover weight-loss drugs like Wegovy and Zepbound for its beneficiaries.

Some of the more than a dozen states that cover the high cost of GLP-1 drugs like Wegovy, Ozempic and Zepbound through ...

The Centers for Medicare and Medicaid Services said late Friday that it would not cover medications such as Wegovy that are ...

People diagnosed with type 2 diabetes might benefit soon from Eli Lilly's new orforglipron weight loss drug following its ...

In a New York Times column this week, the Pennsylvania Democrat shared his experience taking Mounjaro while advocating for ...

Popular weight loss drugs may do more than curb appetite — they may also help reduce the risk of dementia, according to new research.

President Donald Trump has ordered the Department of Health and Human Services to standardize Medicare payments in an effort ...